Company
L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.
Iproteos seeks to improve human health by creating therapeutics for diseases that are currently difficult or impossible to target. We partner with pharmaceutical companies, licensing our proprietary IPROTech platform and our in-house compounds.
Barcelona, Catalonia, Spain
Send a message
Anglais
Anglais
Iproteos is determined to improve human health by creating therapeutics to fulfil unmet medical needs. Our proprietary platform IPROTech allows the development of novel highly permeable and stable compounds to specifically address undruggable targets in less time and cost. The effectiveness of IPROTech has been proved by Iproteos’ pipeline of compounds mainly for Central Nervous System (CNS) indications. Our most advanced program is for Cognitive Impairment related with CNS...
Iproteos is determined to improve human health by creating therapeutics to fulfil unmet medical needs. Our proprietary platform IPROTech allows the development of novel highly permeable and stable compounds to specifically address undruggable targets in less time and cost. The effectiveness of IPROTech has been proved by Iproteos’ pipeline of compounds mainly for Central Nervous System (CNS) indications. Our most advanced program is for Cognitive Impairment related with CNS diseases such as Schizophrenia or Parkinson’s disease, and will enter clinical trials in early 2019.
Website www.iproteos.com
Twitter and Linkedin @iproteos